AbbVie Inc. Non-operating Interest Expenses

Non-operating Interest Expenses of ABBV for past 10 years: annual, quarterly and twelve month trailing (TTM) including Non-operating Interest Expenses growth rates and interactive chart. Interest expense that is usually non-recurring and not tied to a company's operations. It is stated separately on the income statement to differentiate it from interest expenses.


Highlights and Quick Summary

  • Non-operating Interest Expenses for the quarter ending December 30, 2019 was $455 Million (a 8.33% increase compared to previous quarter)
  • Year-over-year quarterly Non-operating Interest Expenses increased by 40.0%
  • Annual Non-operating Interest Expenses for 2019 was $1.51 Billion (a 31.91% increase from previous year)
  • Annual Non-operating Interest Expenses for 2018 was $1.14 Billion (a 13.94% increase from previous year)
  • Annual Non-operating Interest Expenses for 2017 was $1 Billion (a 4.04% increase from previous year)
  • Twelve month Non-operating Interest Expenses ending December 30, 2019 was $1.51 Billion (a 9.91% increase compared to previous quarter)
  • Twelve month trailing Non-operating Interest Expenses increased by 23.89% year-over-year
Trailing Non-operating Interest Expenses for the last four month:
30 Dec '19 29 Sep '19 29 Jun '19 30 Mar '19
$1.51 Billion $1.37 Billion $1.26 Billion $1.22 Billion
Visit stockrow.com/ABBV for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Non-operating Interest Expenses of AbbVie Inc.

Most recent Non-operating Interest Expensesof ABBV including historical data for past 10 years.

Interactive Chart of Non-operating Interest Expenses of AbbVie Inc.

AbbVie Inc. Non-operating Interest Expenses for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2019 $455.0 $420.0 $309.0 $325.0 $1,509.0
2018 $319.0 $302.0 $272.0 $251.0 $1,144.0
2017 $252.0 $252.0 $253.0 $247.0 $1,004.0
2016 $290.0 $250.0 $225.0 $200.0 $965.0
2015 $199.0 $197.0 $164.0 $126.0 $686.0
2014 $129.0 $128.0 $69.0 $65.0 $391.0
2013 $68.0 $69.0 $75.0 $66.0 $278.0
2012 $88.0 $-1.0 $-2.0 $-1.0 $84.0
2011 $-20.0 $0.0 $0.0 $-20.0
2010 $-28.0

Business Profile of AbbVie Inc.

Sector: Medical
Industry: Drugs
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. It offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behcet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstrom's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides KALETRA, an anti-human immunodeficiency virus (HIV)-1 medicine used with other anti-HIV-1 medications to maintain viral suppression in HIV-1 patients; NORVIR, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and SYNAGIS to prevent respiratory syncytial virus infection at-risk infants. In addition, it offers AndroGel, a testosterone replacement therapy; CREON, a pancreatic enzyme therapy; Synthroid to treat hypothyroidism; and Lupron to treat prostate cancer, endometriosis, and central precocious puberty, as well as anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product; and ORILISSA, a non-peptide molecule gonadotropin-releasing hormone antagonist. It has collaborations with Alector, Inc.; Janssen Biotech, Inc.; Galapagos; Bristol-Myers Squibb Company; Calico Life Sciences LLC; Cystic Fibrosis Foundation; Dragonfly Therapeutics, Inc.; and Pan-Canadian Pharmaceutical Alliance. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.